Industry Newspeptide therapeuticsai enabled designphysics based simulationimmunology
Pinnacle Medicines Raises $89M Series B
|
7.1
Pinnacle Medicines today announced the closing of an oversubscribed $89 million Series B financing co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital, Logos Capital and OrbiMed. The Doylestown, PA biotech uses integrated physics-based molecular simulations, AI-enabled design and advanced peptide chemistry to develop oral peptide therapeutics and will advance programs in immunology and cardiometabolic diseases.
Scoring Rationale
Strong Series B funding and AI-physics platform demonstrate potential, limited by single-company announcement and limited technical details.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
